InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Biotechnology and patentability: navigating unchartered waters in Australia and the US


The debate over the patentability of isolated DNA has raged around the world. Tania Obranovich compares the two Myriad decisions from the highest courts in Australia and the US and explains how the Australian decision has called into question what had long been thought of as a fundamental pillar of Australian patent law

Myriad's BRCA patents, which claim both breast cancer diagnostic methods and the isolated BRCA DNA molecules, have courted significant controversy both in Australia and the US in recent years. Extensive judicial consideration in relation to the patent eligibility of isolated...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain FREE access to up to five free articles when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

Our weekly IP news round-up includes NPEs in Europe, AI, sovereign immunity, Section 101, UK trade secrets, and the… https://t.co/1IKhZLv7Gl

Feb 22 2018 03:46 ·  reply ·  retweet ·  favourite
ManagingIP profile

German Constitutional Court plans to decide UPC case in 2018 https://t.co/HURPYcerwS But it is not certain a decisi… https://t.co/pQugzgEtRt

Feb 22 2018 02:04 ·  reply ·  retweet ·  favourite
ManagingIP profile

RT @UPCtracker: This is one of nine (9) cases allocated to Justice Prof Huber (among them consolidated complaint re: adequate legal protect…

Feb 21 2018 05:15 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


null null null

null null null

February 2018

FRAND aid: Is the European Commission’s SEP guidance useful?

Both patent owners and implementers have welcomed the European Commission’s communication on standard essential patents. Does that mean it has successfully balanced competing interests or merely dodged the difficult questions? James Nurton investigates



Most read articles

Supplements